Glioblastoma multiforme (GBM) is the most aggressive and malignant brain tumor. Delicate microenvironment and lineage heterogeneity of GBM cells including infiltration, hypoxia, angiogenesis, and stemness make them highly resistant to current conventional therapies, with an average life expectancy for GBM patients of less than 15 months. Poor response to cytotoxic agents of GBM cells remains the major challenge of GBM treatment. Resistance of GBM to clinical treatment is a result of genomic alternation and deregulated signaling pathways, such as p53 mutation and apoptosis signaling blockage, providing cancer cells more opportunities for survival rather than cell death. WW domain-containing oxidoreductase (WWOX) is a tumor suppressor gene, commonly downregulated in various types of tumors, including GBM. It has been found that the reintroduction of WWOX induced p53-mutant GBM cells to undergo apoptosis, but not in p53 wild-type GBM cells, indicating WWOX is likely to reopen apoptosis pathways in a p53-independent manner in GBM. Identifying the crucial target modulated by WWOX deficiency provides a potential therapeutic target for GBM treatment. Here, we have reviewed the literatures about the role of WWOX in development, signaling pathway, prognosis, and treatment response in malignant glioma.
SmirniotopoulosJG. The new WHO classification of brain tumors. Neuroimaging Clin N Am1999; 9: 595–613.
2.
JarzabekMASweeneyKJEvansRLJacobsAHStuppRO’BrienDBergerMSPrehnJHByrneAT. Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. Drug Discov Today2013; 18: 1052–66.
3.
JovcevskaIKocevarNKomelR. Glioma and glioblastoma – how much do we (not) know?Mol Clin Oncol2013; 1: 935–41.
DunnGPRinneMLWykoskyJGenoveseGQuayleSNDunnIFAgarwallaPKChhedaMGCamposBWangABrennanCLigonKLFurnariFCaveneeWKDepinhoRAChinLHahnWC. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev2012; 26: 756–84.
7.
Romaguera-RosMPeris-CeldaMOliver-De La CruzJCarrion-NavarroJPerez-GarciaAGarcia-VerdugoJMAyuso-SacidoA. Cancer-initiating enriched cell lines from human glioblastoma: preparing for drug discovery assays. Stem Cell Rev2012; 8: 288–98.
8.
EiseleGWellerM. Targeting apoptosis pathways in glioblastoma. Cancer Lett2013; 332: 335–45.
9.
HermansenSKKristensenBW. MicroRNA biomarkers in glioblastoma. J Neurooncol2013; 114: 13–23.
10.
TanakaSLouisDNCurryWTBatchelorTTDietrichJ. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?Nat Rev Clin Oncol2013; 10: 14–26.
11.
CloughesyTFCaveneeWKMischelPS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol2014; 9: 1–25.
12.
SpeidelD. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol2010; 20: 14–24.
13.
OhtaMTateishiKKanaiFWatabeHKondoSGulengBTanakaYAsaokaYJazagAImamuraJIjichiHIkenoueTSataMMiyagishiMTairaKTadaMKawabeTOmataM. p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. Cancer Res2005; 65: 10822–9.
14.
ChiangMFYehSTLiaoHFChangNSChenYJ. Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. Biomed Pharmacother2012; 66: 433–8.
15.
BednarekAKLaflinKJDanielRLLiaoQHawkinsKAAldazCM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res2000; 60: 2140–5.
16.
GloverTWArltMFCasperAMDurkinSG. Mechanisms of common fragile site instability. Hum Mol Genet2005; 14: R197–205.
17.
RiedKFinnisMHobsonLMangelsdorfMDayanSNancarrowJKWoollattEKremmidiotisGGardnerAVenterDBakerERichardsRI. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet2000; 9: 1651–63.
18.
ZarrinparALimWA. Converging on proline: the mechanism of WW domain peptide recognition. Nat Struct Biol2000; 7: 611–3.
19.
Abu-OdehMBar-MagTHuangHKimTSalahZAbdeenSKSudolMReichmannDSidhuSKimPMAqeilanRI. Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. J Biol Chem2014; 289: 8865–80.
ChangJYHeRYLinHPHsuLJLaiFJHongQChenSJChangNS. Signaling from membrane receptors to tumor suppressor WW domain-containing oxidoreductase. Exp Biol Med (Maywood)2010; 235: 796–804.
22.
BrayJEMarsdenBDOppermannU. The human short-chain dehydrogenase/reductase (SDR) superfamily: a bioinformatics summary. Chem Biol Interact2009; 178: 99–109.
23.
ChangNSPrattNHeathJSchultzLSleveDCareyGBZevotekN. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem2001; 276: 3361–70.
24.
BednarekAKKeck-WaggonerCLDanielRLLaflinKJBergsagelPLKiguchiKBrennerAJAldazCM. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res2001; 61: 8068–73.
25.
GardenswartzAAqeilanRI. WW domain-containing oxidoreductase’s role in myriad cancers: clinical significance and future implications. Exp Biol Med (Maywood)2014; 239: 253–63.
26.
MahajanNPWhangYEMohlerJLEarpHS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res2005; 65: 10514–23.
27.
LiuCJShenWGPengSYChengHWKaoSYLinSCChangKW. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int J Cancer2014; 134: 811–21.
28.
WatanabeAHippoYTaniguchiHIwanariHYashiroMHirakawaKKodamaTAburataniH. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res2003; 63: 8629–33.
29.
LaiFJChengCLChenSTWuCHHsuLJLeeJYChaoSCSheenMCShenCLChangNSSheuHM. WOX1 is essential for UVB irradiation-induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squamous cell carcinoma in vivo. Clin Cancer Res2005; 11: 5769–77.
30.
ChenSTChuangJIWangJPTsaiMSLiHChangNS. Expression of WW domain-containing oxidoreductase WOX1 in the developing murine nervous system. Neuroscience2004; 124: 831–9.
31.
NunezMILudes-MeyersJAldazCM. WWOX protein expression in normal human tissues. J Mol Histol2006; 37: 115–25.
32.
Abdel-SalamGThoenesMAfifiHHKorberFSwanDBolzHJ. The supposed tumor suppressor gene WWOX is mutated in an early lethal microcephaly syndrome with epilepsy, growth retardation and retinal degeneration. Orphanet J Rare Dis2014; 9: 12–12.
33.
MallaretMSynofzikMLeeJSagumCAMahajnahMSharkiaRDrouotNRenaudMKleinFAAnheimMTranchantCMignotCMandelJLBedfordMBauerPSalihMASchuleRScholsLAldazCMKoenigM. The tumour suppressor gene WWOX is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation. Brain2014; 137: 411–9.
34.
AqeilanRITrapassoFHussainSCostineanSMarshallDPekarskyYHaganJPZanesiNKaouMSteinGSLianJBCroceCM. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA2007; 104: 3949–54.
35.
SuzukiHTakenakaMSuzukiK. Phenotypic characterization of spontaneously mutated rats showing lethal dwarfism and epilepsy. Comp Med2007; 57: 360–9.
36.
SuzukiHKatayamaKTakenakaMAmakasuKSaitoKSuzukiK. A spontaneous mutation of the Wwox gene and audiogenic seizures in rats with lethal dwarfism and epilepsy. Genes Brain Behav2009; 8: 650–60.
37.
Yu K, Fan J, Ding X, Li C, Wang J, Xiang Y, Wang Q. Association study of a functional copy number variation in the WWOX gene with risk of gliomas among Chinese people. Int J Cancer 2014;135:1687–91.
38.
WinardiWTsaiCYChenWTTsaiHPChungCLLohJKChaiCYKwanAL. Reduced WWOX protein expression in human astrocytoma. Neuropathology2013; 33: 621–7.
39.
SparmannAvan LohuizenM. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer2006; 6: 846–56.
KorurSHuberRMSivasankaranBPetrichMMorinPJrHemmingsBAMerloALinoMM. GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One2009; 4: e7443–e7443.
42.
KimuraMTakenobuHAkitaNNakazawaAOchiaiHShimozatoOFujimuraYKosekiHYoshinoIKimuraHNakagawaraAKamijoT. Bmi1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells. Cancer Sci2011; 102: 983–90.
43.
AqeilanRIHaganJPde BruinARawahnehMSalahZGaudioESiddiquiHVoliniaSAlderHLianJBSteinGSCroceCM. Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology2009; 150: 1530–5.
44.
Ludes-MeyersJHKilHNunezMIContiCJParker-ThornburgJBedfordMTAldazCM. WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Genes Chromosomes Cancer2007; 46: 1129–36.
45.
AbdeenSKDel MareSHussainSAbu-RemailehMSalahZHaganJRawahnehMPuXARussellSSteinJLSteinGSLianJBAqeilanRI. Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype. J Cell Physiol2013; 228: 1377–82.
46.
FergusonBWGaoXKilHLeeJBenavidesFAbbaMCAldazCM. Conditional Wwox deletion in mouse mammary gland by means of two Cre recombinase approaches. PLoS One2012; 7: e36618–e36618.
IliopoulosDFabbriMDruckTQinHRHanSYHuebnerK. Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res2007; 13: 268–74.
49.
GourleyCPaigeAJTaylorKJWardCKuskeBZhangJSunMJanczarSHarrisonDJMuirMSmythJFGabraH. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res2009; 69: 4835–42.
50.
AbdeenSKSalahZKhawaledSAqeilanRI. Characterization of WWOX inactivation in murine mammary gland development. J Cell Physiol2013; 228: 1391–6.
51.
FergusonBWGaoXZelazowskiMJLeeJJeterCRAbbaMCAldazCM. The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding. BMC Cancer2013; 13: 593–593.
52.
QuJLuWLiBLuCWanX. WWOX induces apoptosis and inhibits proliferation in cervical cancer and cell lines. Int J Mol Med2013; 31: 1139–47.
53.
FabbriMIliopoulosDTrapassoFAqeilanRICimminoAZanesiNYendamuriSHanSYAmadoriDHuebnerKCroceCM. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA2005; 102: 15611–6.
54.
ZhouYLLiYCShouFLiuCQPuYTangH. Reversing effect of exogenous WWOX gene expression on malignant phenotype of primary cultured lung carcinoma cells. Chin Med J (Engl)2010; 123: 615–20.
55.
BeckerSMarkovaBWiewrodtRHoffarthSHahnelPSPleinerSSchmidtLHBreitenbuecherFSchulerM. Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer. J Thorac Oncol2011; 6: 1976–83.
56.
ZhangPJiaRYingLLiuBQianGFanXGeS. WWOX-mediated apoptosis in A549 cells mainly involves the mitochondrial pathway. Mol Med Rep2012; 6: 121–4.
57.
QinHRIliopoulosDSembaSFabbriMDruckTVoliniaSCroceCMMorrisonCDKleinRDHuebnerK. A role for the WWOX gene in prostate cancer. Cancer Res2006; 66: 6477–81.
58.
NakayamaSSembaSMaedaNAqeilanRIHuebnerKYokozakiH. Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci2008; 99: 1370–6.
59.
YanHCXueJQLuXYWanMRFengXLiuXY. [Effects of WWOX gene transfection on cell growth of epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi2008; 43: 361–5.
60.
XiongZHuSWangZ. Cloning of WWOX gene and its growth-inhibiting effects on ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci2010; 30: 365–9.
61.
HuBSTanJWZhuGHWangDFZhouXSunZQ. WWOX induces apoptosis and inhibits proliferation of human hepatoma cell line SMMC-7721. World J Gastroenterol2012; 18: 3020–6.
62.
TsaiCWLaiFJSheuHMLinYSChangTHJanMSChenSMHsuPCHuangTTHuangTCSheenMCChenSTChangWCChangNSHsuLJ. WWOX suppresses autophagy for inducing apoptosis in methotrexate-treated human squamous cell carcinoma. Cell Death Dis2013; 4: e792–e792.
63.
MaedaNSembaSNakayamaSYanagiharaKYokozakiH. Loss of WW domain-containing oxidoreductase expression in the progression and development of gastric carcinoma: clinical and histopathologic correlations. Virchows Arch2010; 457: 423–32.
64.
ChangNSDohertyJEnsignASchultzLHsuLJHongQ. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem2005; 280: 43100–8.
65.
ChangNSSchultzLHsuLJLewisJSuMSzeCI. 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene2005; 24: 714–23.
66.
HongQSzeCILinSRLeeMHHeRYSchultzLChangJYChenSJBoackleRJHsuLJChangNS. Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One2009; 4: e5755–e5755.
67.
ThavathiruELudes-MeyersJHMacLeodMCAldazCM. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol Carcinog2005; 44: 174–82.
68.
HuangYCHungWCChenWTYuHSChaiCY. Expression of WWOX and FHIT is downregulated by exposure to arsenite in human uroepithelial cells. Toxicol Lett2013; 220: 118–25.
69.
AqeilanRIPalamarchukAWeigelRJHerreroJJPekarskyYCroceCM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res2004; 64: 8256–61.
70.
AqeilanRIPekarskyYHerreroJJPalamarchukALetofskyJDruckTTrapassoFHanSYMelinoGHuebnerKCroceCM. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA2004; 101: 4401–6.
71.
SalahZBar-magTKohnYPichiorriFPalumboTMelinoGAqeilanRI. Tumor suppressor WWOX binds to DeltaNp63alpha and sensitizes cancer cells to chemotherapy. Cell Death Dis2013; 4: e480–e480.
72.
McDonaldCBBuffaLBar-MagTSalahZBhatVMiklesDCDeeganBJSeldeenKLMalhotraASudolMAqeilanRINawazZFarooqA. Biophysical basis of the binding of WWOX tumor suppressor to WBP1 and WBP2 adaptors. J Mol Biol2012; 422: 58–74.
73.
JinCGeLDingXChenYZhuHWardTWuFCaoXWangQYaoX. PKA-mediated protein phosphorylation regulates ezrin-WWOX interaction. Biochem Biophys Res Commun2006; 341: 784–91.
74.
BouteilleNDriouchKHagePESinSFormstecherECamonisJLidereauRLallemandF. Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein. Oncogene2009; 28: 2569–80.
75.
TakeuchiTAdachiYNagayamaT. A WWOX-binding molecule, transmembrane protein 207, is related to the invasiveness of gastric signet-ring cell carcinoma. Carcinogenesis2012; 33: 548–54.
76.
XiongAWeiLYingMWuHHuaJWangY. Wwox suppresses breast cancer cell growth through modulation of the hedgehog-GLI1 signaling pathway. Biochem Biophys Res Commun2014; 443: 1200–5.
77.
LanYYWuSYLaiHCChangNSChangFHTsaiMHSuIJChangY. WW domain-containing oxidoreductase is involved in upregulation of matrix metalloproteinase 9 by Epstein-Barr virus latent membrane protein 2A. Biochem Biophys Res Commun2013; 436: 672–6.
78.
AqeilanRIDonatiVPalamarchukATrapassoFKaouMPekarskyYSudolMCroceCM. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res2005; 65: 6764–72.
79.
HongQHsuLJSchultzLPrattNMattisonJChangNS. Zfra affects TNF-mediated cell death by interacting with death domain protein TRADD and negatively regulates the activation of NF-kappaB, JNK1, p53 and WOX1 during stress response. BMC Mol Biol2007; 8: 50–50.
80.
AqeilanRIHassanMQde BruinAHaganJPVoliniaSPalumboTHussainSLeeSHGaurTSteinGSLianJBCroceCM. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem2008; 283: 21629–39.
81.
LinHPChangJYLinSRLeeMHHuangSSHsuLJChangNS. Identification of an in vivo MEK/WOX1 complex as a master switch for apoptosis in T cell leukemia. Genes Cancer2011; 2: 550–62.
82.
ChangNSDohertyJEnsignA. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem2003; 278: 9195–202.
83.
ChangNSDohertyJEnsignALewisJHeathJSchultzLChenSTOppermannU. Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem Pharmacol2003; 66: 1347–54.
84.
HsuLJSchultzLHongQVan MoerKHeathJLiMYLaiFJLinSRLeeMHLoCPLinYSChenSTChangNS. Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. J Biol Chem2009; 284: 16049–59.
85.
LiMYLaiFJHsuLJLoCPChengCLLinSRLeeMHChangJYSubhanDTsaiMSSzeCIPugazhenthiSChangNSChenST. Dramatic co-activation of WWOX/WOX1 with CREB and NF-kappaB in delayed loss of small dorsal root ganglion neurons upon sciatic nerve transection in rats. PLoS One2009; 4: e7820–e7820.
86.
GaudioEPalamarchukAPalumboTTrapassoFPekarskyYCroceCMAqeilanRI. Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer Res2006; 66: 11585–9.
87.
WangHYJuoLILinYTHsiaoMLinJTTsaiCHTzengYHChuangYCChangNSYangCNLuPJ. WW domain-containing oxidoreductase promotes neuronal differentiation via negative regulation of glycogen synthase kinase 3beta. Cell Death Differ2012; 19: 1049–59.
88.
AqeilanRIDonatiVGaudioENicolosoMSSundvallMKorhonenALundinJIsolaJSudolMJoensuuHCroceCMEleniusK. Association of Wwox with ErbB4 in breast cancer. Cancer Res2007; 67: 9330–6.
89.
JamshidihaMHabibollahiPOstadSNGhahremaniMH. Primary WWOX phosphorylation and JNK activation during etoposide induces cytotoxicity in HEK293 cells. Daru2010; 18: 141–5.
90.
FuJQuZYanPIshikawaCAqeilanRIRabsonABXiaoG. The tumor suppressor gene WWOX links the canonical and noncanonical NF-kappaB pathways in HTLV-I Tax-mediated tumorigenesis. Blood2011; 117: 1652–61.
91.
O’KeefeLVColellaADayanSChenQChooAJacobRPriceGVenterDRichardsRI. Drosophila orthologue of WWOX, the chromosomal fragile site FRA16D tumour suppressor gene, functions in aerobic metabolism and regulates reactive oxygen species. Hum Mol Genet2011; 20: 497–509.
92.
Chiang MF, Chen ST, Lo CP, Sze CI, Chang NS, Chen YJ. Expression of WW domain-containing oxidoreductase WOX1 in human nervous system tumors. Anal Cell Pathol (Amst) 2013;36:133–47.
93.
YangZZhaoTLiuY. Upregulation of tumor suppressor WWOX promotes immune response in glioma. Cell Immunol2013; 285: 1–5.
94.
BraunSOppermannHMuellerARennerCHovhannisyanABaran-SchmidtRGebhardtRHipkissAThieryJMeixensbergerJGaunitzF. Hedgehog signaling in glioblastoma multiforme. Cancer Biol Ther2012; 13: 487–95.
95.
SantoniMBurattiniLNabissiMMorelliMBBerardiRSantoniGCascinuS. Essential role of Gli proteins in glioblastoma multiforme. Curr Protein Pept Sci2013; 14: 133–40.
96.
ZhuHCarpenterRLHanWLoHW. The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth. Cancer Lett2014; 343: 51–61.
97.
DrenkhahnSKJacksonGASlusarzAStarkeyNJLubahnDB. Inhibition of hedgehog/Gli signaling by botanicals: a review of compounds with potential hedgehog pathway inhibitory activities. Curr Cancer Drug Targets2013; 13: 580–95.
98.
SunYGuoWRenTLiangWZhouWLuQJiaoGYanT. Gli1 inhibition suppressed cell growth and cell cycle progression and induced apoptosis as well as autophagy depending on ERK1/2 activity in human chondrosarcoma cells. Cell Death Dis2014; 5: e979–e979.
99.
WongAJBignerSHBignerDDKinzlerKWHamiltonSRVogelsteinB. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA1987; 84: 6899–903.
100.
NishikawaRJiXDHarmonRCLazarCSGillGNCaveneeWKHuangHJ. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA1994; 91: 7727–31.
101.
PoreNJiangZGuptaACernigliaGKaoGDMaityA. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res2006; 66: 3197–204.
102.
DuerrEMRollbrockerBHayashiYPetersNMeyer-PuttlitzBLouisDNSchrammJWiestlerODParsonsREngCvon DeimlingA. PTEN mutations in gliomas and glioneuronal tumors. Oncogene1998; 16: 2259–64.
103.
LiJYenCLiawDPodsypaninaKBoseSWangSIPucJMiliaresisCRodgersLMcCombieRBignerSHGiovanellaBCIttmannMTyckoBHibshooshHWiglerMHParsonsR. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science1997; 275: 1943–7.
104.
LiJYWangHMaySSongXFueyoJFullerGN. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J Neurooncol2008; 88: 11–7.
105.
AntonyakMAMoscatelloDKWongAJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem1998; 273: 2817–22.
106.
BonaviaRIndaMMVandenbergSChengSYNaganeMHadwigerPTanPSahDWCaveneeWKFurnariFB. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. Oncogene2012; 31: 4054–66.
107.
JiangYBoijeMWestermarkBUhrbomL. PDGF-B can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. Neoplasia2011; 13: 492–503.
108.
JooKMJinJKimEHo KimKKimYGu KangBKangYJLathiaJDCheongKHSongPHKimHSeolHJKongDSLeeJIRichJNLeeJNamDH. MET signaling regulates glioblastoma stem cells. Cancer Res2012; 72: 3828–38.
109.
De BaccoFCasanovaEMedicoEPellegattaSOrzanFAlbanoRLuraghiPReatoGD’AmbrosioAPorratiPPataneMMadernaEPolloBComoglioPMFinocchiaroGBoccaccioC. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res2012; 72: 4537–50.
110.
ChennAWalshCA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science2002; 297: 365–9.
PulvirentiTVan Der HeijdenMDromsLAHuseJTTabarVHallA. Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res2011; 71: 7280–90.
113.
Barcellos-HoffMH. Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res1993; 53: 3880–6.
114.
EhrhartEJSegariniPTsangMLCarrollAGBarcellos-HoffMH. Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation. Faseb J1997; 11: 991–1002.
115.
WangJZhengHSungCCRichterKKHauer-JensenM. Cellular sources of transforming growth factor-beta isoforms in early and chronic radiation enteropathy. Am J Pathol1998; 153: 1531–40.
BaritakiSChatzinikolaAMVakisAFSoulitzisNKarabetsosDANeonakisIBonavidaBSpandidosDA. YY1 Over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels. Cancer Invest2009; 27: 184–92.
119.
DriouchKPrydzHMoneseRJohansenHLidereauRFrengenE. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene2002; 21: 1832–40.
120.
GourleyCPaigeAJTaylorKJScottDFrancisNJRushRAldazCMSmythJFGabraH. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol2005; 26: 1681–9.
121.
StranoSMunarrizERossiMCastagnoliLShaulYSacchiAOrenMSudolMCesareniGBlandinoG. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem2001; 276: 15164–73.
122.
OmerovicJPuggioniEMNapoletanoSViscoVFraioliRFratiLGulinoAAlimandiM. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res2004; 294: 469–79.
123.
ZaidiSKSullivanAJMedinaRItoYvan WijnenAJSteinJLLianJBSteinGS. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. Embo J2004; 23: 790–9.
124.
KomuroANagaiMNavinNESudolM. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem2003; 278: 33334–41.
125.
YagiRChenLFShigesadaKMurakamiYItoY. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J1999; 18: 2551–62.
126.
KhouryMPBourdonJC. The isoforms of the p53 protein. Cold Spring Harb Perspect Biol2010; 2: a000927–a000927.
127.
Del MareSSalahZAqeilanRI. WWOX: its genomics, partners, and functions. J Cell Biochem2009; 108: 737–45.
128.
SalahZAqeilanRHuebnerK. WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol2010; 6: 249–59.
